Showing posts with label cancer research journals. Show all posts
Showing posts with label cancer research journals. Show all posts

Tuesday, 11 July 2017

Breast Cancer and Pregnancy: Experience of Maternity and Neonatology Center of Tunis-Tunisia

This document aims to identify the clinical, therapeutic, and prognostic features of this association and to provide the up-to-date management.

Breast Cancer

Our study design is retrospective based on 25 cases of pregnancy-associated breast cancer, carried out at the Maternity and Neonatology Center of Tunis over a period of 10 years, between January 2001 and December 2013.

The mean age of the patients was 35.84 years. Breast cancer was diagnosed during pregnancy in fourteen patients and after delivery in eleven patients. Pathohistological diagnosis was established by ultrasoundguided biopsy and surgical biopsy in fourteen and seven patients, respectively.


Monday, 29 May 2017

The Relationship Between Smoking and Cancer: Mini Review

Relationship Between Smoking and Cancer
Once the word ‘’cancer’’ is heard, it triggers fear and anxiety. Millions of people have lost their lives because of this illness.
Although improvement of technology in recent years help the medicine for obtaining pleasing results, the reasons of this horrifying and cruel illness cannot be revealed as diagnosis.
Therefore, for every cancer type the cure might not be possible. In this article of ours, we will evaluate the relationship of cancer with smoking in the latest information which is the most important factor of cancer and said ‘’a bad habit’’ in medicine literature.

Wednesday, 24 May 2017

Metaplastic Breast Cancer and p16 Positivity: What Does It Mean?

Metaplastic breast cancer is a heterogeneous group of malignant breast tumors having different morphologic subtypes. Considerable variations exist in different ethnic groups.
Metaplastic Breast Cancer

The incidence of metaplastic breast cancer is reported to be 0.2-1 percent of breast cancer and it is rare in the west.

MBC is referred to tumor when conventional breast carcinoma contains a metaplastic component ranging from <10% - >50%

Thursday, 4 May 2017

Current Exercise Behaviors Of Breast Cancer Patients Diagnosed With Chemotherapy-induced Peripheral Neuropathy

Chemotherapy- induced peripheral neuropathy (CIPN) is a common ailment among those taking chemotherapeutic drugs. This condition is characterized by damage to the nervous system that is a direct result of the medications associated with chemotherapy.

Little is known about the mechanisms responsible for the development of CIPN. The peripheral toxicity involved with CIPN is specific to each chemotherapy drug class, and in most cases, appears to be dose and duration dependent, however it can evolve even after a single drug application.
Chemotherapy- induced peripheral neuropathy (CIPN) is a common ailment among those taking chemotherapeutic drugs. This condition is characterized by damage to the nervous system that is a direct result of the medications associated with chemotherapy.  Little is known about the mechanisms responsible for the development of CIPN. The peripheral toxicity involved with CIPN is specific to each chemotherapy drug class, and in most cases, appears to be dose and duration dependent, however it can evolve even after a single drug application.  The chemotherapy agents Docetaxel, Paclitaxel, or Vinorelbine are used to treat breast cancer, and often result in damage to central nervous system pain pathways, resulting in neuropathic pain. PDF LINK

The chemotherapy agents Docetaxel, Paclitaxel, or Vinorelbine are used to treat breast cancer, and often result in damage to central nervous system pain pathways, resulting in neuropathic pain.

Wednesday, 26 October 2016

Cervical cancer screening strategies

Starting from May 1, 2017 in Australia the National Cervical Screening Program will shift from cervical cytology every two years, to HPV DNA testing as the sole primary screening test every five years in women aged 25 to 74 years, together with the implementation of an active HPV vaccination program.

Cervical cancer Conversely in Japan cervical screening using cytology every two years is still being recommended for population-based and opportunistic screening. While Canadian guidelines also recommend cervical screening with cytology every 3 years, in Europe cervical cytology is recommended for women under 30-35 years, and HPV testing as the sole primary screening test every 5-10 years for women above 30-35 years.

Actually, guidelines do not represent the real situation in each European country. In the Netherlands, screening is well organised and relies on primary HPV testing every 5 years until 40 years of age and every 10 years for women aged 40 and beyond: no screening is provided for women under 30, nor over 60 years of age.

Tuesday, 4 October 2016

Eradicating Health Care Disparities in the Surgical Management of Prostate Cancer

Racial disparities in prostate cancer epidemiology and survival outcomes generally have been well documented, with assorted facts and figures indicating that African-American men are disadvantaged with regard to disease control and therapeutic gains associated with this disease relative to their Caucasian-American counterparts.

Prostate Cancer
Prostate cancer is a daunting disease state for all Americans it represents the most commonly diagnosed malignancy and the second most common cause of cancer-related deaths in the United States. However, for African-American men, the public health implications of this disease are all the more sobering: the disease incidence is 1.62-fold greater for African-American men than for Caucasian-American men and the mortality rate-ratio is 2.45-fold greater, respectively.

In blunt absolute terms, 1 in 3 African-American men will be at risk for developing clinically significant prostate cancer and as much as 1 in 5 African-American men >50 years of age will die of this disease.

Monday, 3 October 2016

The Utility and Applicability of Chronic Myeloid Leukemia Scoring Systems for Predicting the Prognosis of Egyptian Patients on Imatinib

Chronic myeloid leukemia (CML) is myeloproliferative clonal neoplasm with pluripotent hematopoietic stem cell origin. BCR-ABL fusion gene results from a balanced reciprocal translocation between BCR (Breakpoint cluster region) and ABL (Abelson) genes is the main finding in CML.

Chronic Myeloid Leukemia
Transposition of ABL proto-oncogene from chromosome 9 to BCR on chromosome 22 is either at chromosome level [Philadelphia (Ph) chromosome t(9;22)(q34;q11)] or cryptic at gene level. BCR-ABL encodes an unregulated, cytoplasm-targeted tyrosine kinase, leading to uninhibited cell proliferation.

CML is a triphasic disease, chronic-phase (CP), accelerated-phase (AP), and blast-phase (BP). Most patients are asymptomatic and diagnosed in CP; most patients will progress to rapidly fatal BP within 3–5 years if untreated.

Friday, 30 September 2016

Childhood Cancer Care in Developing Countries

Dealing with children who have cancer in developing countries is a great human experience not only for the patient and the family but also for persons who are caring them.The diagnosis of a child as a cancer case is really a great shock to all family members and it is a moment of a dramatic change in their life. First reaction is usually a combination of sadness and denial.

Childhood Cancer Care
They will start a new style of life with a plenty of investigations, appointments and different treatments decisions and plans. Different negative emotional reactions are the classic feelings of the parents every time they meet the treating physician. As caring doctors our role is not only treatment, but to help parents to overcome these initial shock stage and these negative emotions to support them to focus on what they should do to help and support their child through this hard time.

One of the hardest parts of caring for such kids is knowing what to say and how much information to give, as children might be frightened and uncertain of many things, they might be frightened of being died, and here we must assure them. Comforting them is very essential in treatment, although for us it's always heartbreaking.

Tuesday, 20 September 2016

Male Breast Cancer

Breast is made up of glands called lobules that can make milk and thin tubes called ducts that carry the milk from the lobules to the nipple. Breast tissue also contains fat and connective tissue, lymph nodes, and blood vessels.Bosom tumor for the most part begins off in the inward covering of milk pipes or the lobules that supply them with milk.

Male Breast Cancer
A harmful tumor can spread to different parts of the body.The main indication of bosom growth regularly is a bosom protuberance or an anomalous mammogram. Bosom disease stages range from right on time, treatable bosom malignancy to metastatic bosom growth.


Breast cancer is one of the most common malignancies in women but is relatively rare in men with an incidence rate of 0.5% compared to female breast cancer. The risk of breast cancer in male increases with age and men usually present with later stage of disease those results in a worse outcome.

Friday, 16 September 2016

The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3 and their Impact on Recurrence in Breast Cancer Patients

The presence of tumor-infiltrating lymphocytes (TILs) either within the tumor stroma or tumor epithelium reflects the immune response of the host against the tumor, defined as cancer “immunoediting”. Large tumors are in the “escape” phase during which immune cells are not able to stop tumor growth but their presence at least denotes standby immunocompetency which can be reactivated by treatment.

Breast Cancer Patients
Many TILs have been recognized. Of those, fork head box P3- positive (Foxp3+) regulatory T cells (Tregs), CD8+ T cells, and CD4+ T cells are known to be the main keys for immune surveillance and tolerance, respectively [4]. CD8+ T cells are mediators of antitumor immunity and can lyse tumor cells directly. The clinical importance of CD8+ T cells has been suggested by many recent studies that reported a survival benefit in correlation with an increase in CD8+ T cells in large cohorts of various human cancer patients.

CD4+ T cells have an important role in antitumor immunity that was implicated by their helper or memory cell functions. CD4+ T cells may have several effector functions, such as priming tumor-specific cytotoxic T cells or macrophages that are involved in clearance of tumor cells. In contrast, Tregs are known to have a very important role in escape of antitumor T-cell response in cancer cells [13], due to their ability to potently suppress immune reaction against tumors in vivo.

Tuesday, 13 September 2016

Small Cell Carcinoma of the Rectum, A Systematic Literature Review and Case Series

Small cell carcinomas (SmCC) are malignancies that derive from neuroendocrine cells. The World Health Organisation (WHO) in 2010 classified SmCC as a subgroup of neuroendocrine carcinoma (NEC) which accounts for approximately 0.6 percent of all colorectal cancers. NEC has two histologic subgroups, namely large cell carcinoma (LCC) and small cell carcinoma (SmCC). LCC can be difficult to distinguish from poorly differentiated adenocarcinoma.

Small Cell Carcinoma
Despite the fact that the gastrointestinal tract (GI) has the largest number of neuroendocrine cells in the body it is unusual for such malignancies to occur here. First described in 1952, nearly 650 cases of gastrointestinal SmCC have been reported in the literature until 2007. The oesophagus is the commonest site of incidence of GI SmCC (53%) followed by the colon (13%), stomach (11%), gallbladder (8.4%) and rectum (7.3%). The aggressive neoplastic nature of SmCC is characterised by rapid growth, high mitotic proliferation rate (>20 mitotic figures per 10 high-power fields [HPF] or a Ki-67 index >20%), early dissemination and poor prognosis.


SmCC of the rectum is an extrapulmonary small cell carcinoma (EPSmCC) entity, which morphologically resembles pulmonary small cell carcinoma (PSmCC). SmCC was originally thought to derive from amine-precursor uptake and decarboxylase cells (APUD). However, the pluripotent stem cell, with its potential for variable differentiation, is now the most widely accepted theory [6-9]. Although it is important to rule out a PSmCC as the primary tumour the treatment paradigm for EPSmCC is extrapolated form the platinum based therapy used to treat PSmCC .

Thursday, 8 September 2016

Small Cell Carcinoma of the Rectum, A Systematic Literature Review and Case Series

Small cell carcinomas (SmCC) are malignancies that derive from neuroendocrine cells. The World Health Organisation (WHO) in 2010 classified SmCC as a subgroup of neuroendocrine carcinoma (NEC) which accounts for approximately 0.6 percent of all colorectal cancers. NEC has two histologic subgroups, namely large cell carcinoma (LCC) and small cell carcinoma (SmCC). LCC can be difficult to distinguish from poorly differentiated adenocarcinoma.

Literature Review and Case Series

Despite the fact that the gastrointestinal tract (GI) has the largest number of neuroendocrine cells in the body it is unusual for such malignancies to occur here. First described in 1952, nearly 650 cases of gastrointestinal SmCC have been reported in the literature until 2007. The oesophagus is the commonest site of incidence of GI SmCC (53%) followed by the colon (13%), stomach (11%), gallbladder (8.4%) and rectum (7.3%). The aggressive neoplastic nature of SmCC is characterised by rapid growth, high mitotic proliferation rate (>20 mitotic figures per 10 high-power fields [HPF] or a Ki-67 index >20%), early dissemination and poor prognosis.


SmCC of the rectum is an extrapulmonary small cell carcinoma (EPSmCC) entity, which morphologically resembles pulmonary small cell carcinoma (PSmCC). SmCC was originally thought to derive from amine-precursor uptake and decarboxylase cells (APUD). However, the pluripotent stem cell, with its potential for variable differentiation, is now the most widely accepted theory.